EDAP TMS SA to Announce Third Quarter 2022 Financial Results on Wednesday, November 16th, 2022

Rhea-AI Summary

EDAP TMS SA (Nasdaq: EDAP) will release its third-quarter financial results for the period ending September 30, 2022, on November 16, 2022, after market close. A conference call will follow on November 17, 2022, at 8:30 AM EDT, featuring key executives including Marc Oczachowski, Ryan Rhodes, and François Dietsch. The company is recognized for its innovations in robotic energy-based therapies, particularly in the ultrasound market, offering products such as Focal One® and ExactVu™ for prostate cancer treatment.

Positive

• Innovative products like Focal One and ExactVu provide a comprehensive solution for prostate cancer diagnosis and treatment.
• Leader in the therapeutic ultrasound market, enhancing credibility and market position.

Negative

• None.

Company to host conference call and webcast on Thursday, November 17^th at 8:30 am EDT

LYON, France, November 2, 2022 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, today announced that it will release its financial results for the third quarter ended September 30^th after the markets close on Wednesday, November 16^th, 2022.

An accompanying conference call and webcast will be hosted by Marc Oczachowski, Chairman of the Board and Chief Executive Officer, Ryan Rhodes, CEO of EDAP U.S., and François Dietsch, Chief Financial Officer. The call will be held at 8:30am EDT on Thursday, November 17^th, 2022. Please refer to the information below for conference call dial-in information and webcast registration.

Conference Call & Webcast
Thursday, November 17^th @ 8:30am Eastern Time
Domestic:        877-451-6152
International:   201-389-0879
Passcode:        13733576
Webcast:        https://viavid.webcasts.com/starthere.jsp?ei=1576059&tp_key=6f7ca662d1

About EDAP TMS SA

A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology. By combining the latest technologies in imaging and treatment modalities in its complete range of Robotic HIFU devices, EDAP TMS introduced the Focal One® in Europe and in the U.S. as an answer to all requirements for ideal prostate tissue ablation. With the addition of the ExactVu™ Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer. EDAP TMS also produces and distributes other medical equipment including the Sonolith® i-move lithotripter and lasers for the treatment of urinary tract stones using extra-corporeal shockwave lithotripsy (ESWL). For more information on the Company, please visit http://www.edap-tms.com, us.hifu-prostate.com and www.focalone.com.

Company contact:
Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 50
bconfort@edap-tms.com

Investor Contact
John Fraunces
LifeSci Advisors, LLC
212-915-2568
jfraunces@lifesciadvisors.com

FAQ

When will EDAP TMS release its third quarter financial results?

EDAP TMS will release its third quarter financial results on November 16, 2022, after market close.

What time is the EDAP TMS conference call scheduled?

The conference call for EDAP TMS is scheduled for November 17, 2022, at 8:30 AM EDT.

Who will be speaking during the EDAP TMS conference call?

Marc Oczachowski, Ryan Rhodes, and François Dietsch will speak during the EDAP TMS conference call.

What products does EDAP TMS offer for prostate cancer treatment?

EDAP TMS offers the Focal One and ExactVu devices for the diagnosis and treatment of prostate cancer.